MICHAEL BROWN: Open Payments
NPI 1508820119 · ROCHESTER, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,688 in 100 payments from 14 companies in 2025. Trend: 2023 $3,828 · 2024 $4,742 · 2025 $3,688
Food & beverage: $3,578Education: $110
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 29 | $644 |
| Novartis Pharmaceuticals Corporation | 15 | $598 |
| ABBVIE INC. | 18 | $582 |
| Amgen Inc. | 7 | $335 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 5 | $191 |
| Lilly USA, LLC | 4 | $181 |
| GENZYME CORPORATION | 8 | $180 |
| Galderma Laboratories, L.P. | 4 | $172 |
| Incyte Corporation | 2 | $159 |
| Janssen Biotech, Inc. | 3 | $150 |
Products named: Bimzelx, Otezla, SKYRIZI, COSENTYX, RINVOQ, DUPIXENT, ILUMYA, NEMLUVIO.
Industry payments across NY — which companies pay providers there.
